vs
Side-by-side financial comparison of COASTAL FINANCIAL CORP (CCB) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $138.0M, roughly 1.2× COASTAL FINANCIAL CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -5.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -3.6%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CCB vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $138.0M | $168.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 12.4% | 50.6% |
| Net Margin | — | — |
| Revenue YoY | -5.8% | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.84 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $138.0M | $168.4M | ||
| Q3 25 | $144.7M | $87.3M | ||
| Q2 25 | $119.4M | $82.4M | ||
| Q1 25 | $139.5M | $65.0M | ||
| Q4 24 | $146.5M | $69.1M | ||
| Q3 24 | $151.1M | $51.6M | ||
| Q2 24 | $135.3M | $73.8M | ||
| Q1 24 | $148.4M | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | $13.6M | $-31.3M | ||
| Q2 25 | $11.0M | $-12.7M | ||
| Q1 25 | $9.7M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | $-29.5M | ||
| Q2 24 | $11.6M | $-61.9M | ||
| Q1 24 | $6.8M | $61.0M |
| Q4 25 | 12.4% | 50.6% | ||
| Q3 25 | 12.4% | -11.4% | ||
| Q2 25 | 12.0% | 8.6% | ||
| Q1 25 | 8.4% | -34.0% | ||
| Q4 24 | 11.7% | -6.4% | ||
| Q3 24 | 10.8% | -31.0% | ||
| Q2 24 | 11.1% | 3.5% | ||
| Q1 24 | 5.9% | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | 9.4% | -35.9% | ||
| Q2 25 | 9.2% | -15.4% | ||
| Q1 25 | 7.0% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | -57.2% | ||
| Q2 24 | 8.6% | -83.9% | ||
| Q1 24 | 4.6% | 44.3% |
| Q4 25 | $0.84 | $0.32 | ||
| Q3 25 | $0.88 | $-0.16 | ||
| Q2 25 | $0.71 | $-0.06 | ||
| Q1 25 | $0.63 | $-0.21 | ||
| Q4 24 | $0.95 | $-0.14 | ||
| Q3 24 | $0.97 | $-0.15 | ||
| Q2 24 | $0.84 | $-0.33 | ||
| Q1 24 | $0.50 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $491.0M | $-302.0M |
| Total Assets | $4.7B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $491.0M | $-302.0M | ||
| Q3 25 | $475.3M | $-451.4M | ||
| Q2 25 | $461.7M | $-433.5M | ||
| Q1 25 | $449.9M | $-426.2M | ||
| Q4 24 | $438.7M | $-388.7M | ||
| Q3 24 | $331.9M | $-370.2M | ||
| Q2 24 | $316.7M | $-344.2M | ||
| Q1 24 | $303.7M | $-294.3M |
| Q4 25 | $4.7B | $465.9M | ||
| Q3 25 | $4.6B | $364.0M | ||
| Q2 25 | $4.5B | $347.1M | ||
| Q1 25 | $4.3B | $324.0M | ||
| Q4 24 | $4.1B | $343.8M | ||
| Q3 24 | $4.1B | $314.1M | ||
| Q2 24 | $4.0B | $352.3M | ||
| Q1 24 | $3.9B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $254.6M | $45.2M |
| Free Cash FlowOCF − Capex | $246.1M | — |
| FCF MarginFCF / Revenue | 178.3% | — |
| Capex IntensityCapex / Revenue | 6.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $436.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $254.6M | $45.2M | ||
| Q3 25 | $59.0M | $-4.3M | ||
| Q2 25 | $66.0M | $-31.4M | ||
| Q1 25 | $71.7M | $-22.6M | ||
| Q4 24 | $259.8M | $-35.0M | ||
| Q3 24 | $62.6M | $-35.3M | ||
| Q2 24 | $72.1M | $-7.2M | ||
| Q1 24 | $56.8M | $53.8M |
| Q4 25 | $246.1M | — | ||
| Q3 25 | $57.4M | — | ||
| Q2 25 | $64.0M | — | ||
| Q1 25 | $68.9M | — | ||
| Q4 24 | $249.9M | — | ||
| Q3 24 | $60.2M | $-35.5M | ||
| Q2 24 | $69.5M | $-7.3M | ||
| Q1 24 | $55.0M | $53.8M |
| Q4 25 | 178.3% | — | ||
| Q3 25 | 39.7% | — | ||
| Q2 25 | 53.6% | — | ||
| Q1 25 | 49.4% | — | ||
| Q4 24 | 170.6% | — | ||
| Q3 24 | 39.8% | -68.7% | ||
| Q2 24 | 51.3% | -9.9% | ||
| Q1 24 | 37.1% | 39.0% |
| Q4 25 | 6.1% | 0.0% | ||
| Q3 25 | 1.2% | 0.0% | ||
| Q2 25 | 1.7% | 0.0% | ||
| Q1 25 | 2.0% | 0.0% | ||
| Q4 24 | 6.8% | 0.0% | ||
| Q3 24 | 1.6% | 0.3% | ||
| Q2 24 | 1.9% | 0.1% | ||
| Q1 24 | 1.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
